Table 2 Demographic and clinical characteristics of the patients.

From: Survival and recurrence with or without axillary dissection in patients with invasive breast cancer and sentinel node metastasis

 

Group

p

SLND

ALND

N

%

N

%

Race

56

100.0%

41

100.0%

0.120a

White

47

83.9%

28

68.3%

 

Mixed

7

12.5%

10

24.4%

 

Black

1

1.8%

3

7.3%

 

Other

1

1.8%

0

0.0%

 

Educational level

49

100.0%

41

100.0%

0.142a

Illiterate

0

0.0%

1

2.4%

 

Elementary

23

46.9%

27

65.9%

 

High School

13

26.5%

7

17.1%

 

Higher education

13

26.5%

6

14.6%

 

Tumor type

56

100.0%

41

100.0%

0.210a

Infiltrating ductal carcinoma

55

98.2%

37

90.2%

 

Invasive lobular carcinoma

1

1.8%

3

7.3%

 

In situ ductal carcinoma with microinvasion

0

0.0%

1

2.4%

 

Outros

0

0.0%

0

0.0%

 

Histological grade

56

100.0%

41

100.0%

0.983

G1

17

30.4%

13

31.7%

 

G2

27

48.2%

19

46.3%

 

G3

12

21.4%

9

22.0%

 

Immunohistochemistry (hormonal receptors)

56

100.0%

41

100.0%

0.708a

ER + PR + 

44

78.6%

31

75.6%

 

ER + PR −

3

5.4%

3

7.3%

 

ER − PR + 

2

3.6%

0

0.0%

 

ER − PR −

7

12.5%

7

17.1%

 

Immunohistochemistry (HER2)

56

100.0%

41

100.0%

0.695a

HER 2 −

53

94.6%

38

92.7%

 

HER 2 + 

3

5.4%

3

7.3%

 

Pathological staging: tumor size (pT)

56

100.0%

41

100.0%

0.334a

T0

0

0.0%

0

0.0%

 

Tis*

1

1.8%

0

0.0%

 

T1

36

64.3%

22

53.7%

 

T2

19

33.9%

19

46.3%

 

T3

0

0.0%

0

0.0%

 

Pathological staging: nodes (pN)

56

100.0%

41

100.0%

 < 0.001a

N0

0

0.0%

0

0.0%

 

N0 i + 

1

1.8%

0

0.0%

 

N1mi

20

35.7%

1

2.4%

 

N1

35

62.5%

30

73.2%

 

N2

0

0.0%

8

19.5%

 

N3

0

0.0%

2

4.9%

 

Angiolymphatic invasion

56

100.0%

41

100.0%

0.641

Yes

26

46.4%

21

51.2%

 

No

30

53.6%

20

48.8%

 

Capsular extension

56

100.0%

41

100.0%

 < 0.001

Yes

5

8.9%

17

41.5%

 

No

51

91.1%

24

58.5%

 

Axillary metastasis

56

100.0%

41

100.0%

 < 0.001a

Micrometastasis

20

35.7%

1

2.4%

 

Macrometastasis

35

62.5%

40

97.6%

 

Isolated tumoral cell

1

1.8%

0

0.0%

 

Adjuvant chemotherapy

56

100.0%

41

100.0%

0.024

No

14

25.0%

3

7.3%

 

Yes

42

75.0%

38

92.7%

 

Radiotherapy

56

100.0%

41

100.0%

0.080a

No

1

1.8%

5

12.2%

 

Yes

55

98.2%

36

87.8%

 

Tangential fields

39

70.0%

27

66.0%

0.12

Tangential fields and drains

7

12.5%

2

4.9%

 

Unknown

9

16.0%

7

17.0%

 

Hormonal therapy

56

100.0%

41

100.0%

0.896

No

9

16.1%

7

17.1%

 

Yes

47

83.9%

34

82.9%

 
  1. Bold values indicates category headings and the total value of the category by group.
  2. T0 no evidence of primary tumor, Tis ductal carcinoma in situ, T1 tumor size is 2 cm or less across, T2 tumor size 20–50 mm, T3 tumor size is more than 5 cm across, N0 i +  the area of cancer spread contains fewer than 200 isolated tumor cells and is smaller than 0.2 mm (cancer cells seen in routine stains or immunohistochemistry), N1mi micrometastasis to lymph node, N1 1–3 lymph nodes affected, N2 4–9 lymph nodes affected, N3 10 or more lymph nodes affected, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor.
  3. *This patient had her whole 0.5 cm invasive tumor removed during percutaneous biopsy. However, she was later classified clinically as T1a.
  4. aChi-squared or Fisher's exact test.
Back to article page